Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Antibiot (Tokyo) ; 64(9): 649-54, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21792211

RESUMEN

We describe the identification of novel rapamycin derivatives present as low-level impurities in active pharmaceutical ingredients using an integrated, multidisciplinary approach. Rapamycin, a fermentation-derived natural product is itself used clinically and provides the starting material for several rapamycin analog drugs, typically used in oncology. LC-MS proved a sensitive means to analyze impurity profiles in batches of rapamycin. MS fragmentation was used to gain structural insight into these impurities, usually fermentation by-products, structurally very similar to rapamycin. In cases where MS fragmentation was unable to provide unambiguous structural identification, the impurities were isolated and purified using orthogonal HPLC methods. Using the higher mass sensitivity of small-volume NMR microprobes, submilligram amounts of isolated impurities were sufficient for further characterization by multidimensional NMR spectroscopy. Full assignment of the (1)H and (13)C NMR signals revealed the structure of these impurities at an atomic level. This systematic workflow enabled the identification of several novel rapamycin congeners from active pharmaceutical ingredient without the need for large-scale isolation of impurities. For illustration, two novel rapamycin derivatives are described in this study: 12-ethyl-rapamycin and 33-ethyl-rapamycin, which exemplify previously unreported modifications on the carbon skeleton of the rapamycin macrocycle. The methodologies described here can be of wide use for identification of closely related structures found; for example as fermentation by-products, metabolites or degradants of natural product-based drugs.


Asunto(s)
Cromatografía Liquida/métodos , Contaminación de Medicamentos , Preparaciones Farmacéuticas/química , Sirolimus/química , Espectrometría de Masas en Tándem/métodos , Cromatografía Líquida de Alta Presión/métodos , Espectroscopía de Resonancia Magnética , Preparaciones Farmacéuticas/análisis , Sirolimus/aislamiento & purificación
2.
Blood ; 105(4): 1424-30, 2005 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-15507527

RESUMEN

Gene therapy is a potential route for the delivery of secreted therapeutic proteins, but pharmacologic control of expression will generally be required for optimal safety and efficacy. Previous attempts to achieve regulated expression in large animal models have been thwarted by transient expression or immune responses to regulatory proteins. We evaluated the ability of the dimerizer-regulated gene expression system to achieve controlled, long-term production of erythropoietin (Epo) following intramuscular administration of adeno-associated virus (AAV) vectors to 16 primates. All animals showed dose-responsive and completely reversible elevation of Epo and hematocrit in response to the dimerizer rapamycin, or analogs with reduced immunosuppressive activity, administered intravenously or orally. Animals that received optimized dual vectors showed persistent regulated expression for the duration of the study, with no apparent immune response to Epo or the regulatory proteins. Similar results were obtained with single vectors incorporating both the Epo and regulatory genes, including those packaged into serotype 1 AAV vectors to allow use of lower viral doses. For the longest-studied animal, regulated expression has persisted for more than 6 years and 26 induction cycles. These data indicate that one-time or infrequent gene transfer followed by dimerizer regulation is a promising approach for delivery of therapeutic proteins.


Asunto(s)
Dependovirus/genética , Eritropoyetina/biosíntesis , Eritropoyetina/genética , Regulación de la Expresión Génica/efectos de los fármacos , Técnicas de Transferencia de Gen , Administración Oral , Animales , Citomegalovirus/genética , Dependovirus/clasificación , Relación Dosis-Respuesta a Droga , Vectores Genéticos , Rechazo de Injerto/etiología , Inmunosupresores/administración & dosificación , Inmunosupresores/farmacología , Inyecciones Intramusculares , Macaca mulatta , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Serotipificación , Sirolimus/administración & dosificación , Sirolimus/análogos & derivados , Sirolimus/farmacología , Trasplante de Piel/inmunología , Factores de Tiempo
3.
Bioorg Med Chem Lett ; 13(19): 3181-4, 2003 Oct 06.
Artículo en Inglés | MEDLINE | ID: mdl-12951089

RESUMEN

New synthetic chemical inducers of dimerization, comprising homodimeric FKBP ligands with engineered specificity for the designed point mutant F36V, have been evaluated for inducing targeted gene expression in mammalian cells. Structure-activity studies indicated that high-affinity dimerizers such as AP1903 are ineffective, perhaps due to kinetic trapping of non-productive dimers, whereas lower-affinity molecules, exemplified by AP1889 and AP1966, potently activate transcription.


Asunto(s)
Reactivos de Enlaces Cruzados/síntesis química , Reactivos de Enlaces Cruzados/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Tacrolimus/análogos & derivados , Tacrolimus/síntesis química , Tacrolimus/farmacología , Dimerización , Regulación de la Expresión Génica/fisiología , Humanos , Compuestos Orgánicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...